C4 Therapeutics, Inc.: Clinical Trials

2 recruiting, 1 active not recruiting, 1 completed, 1 terminated. 4 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	4	Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1
Phase 2	1	Recruiting 1

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma Cemsidomide, Dexamethasone - Multiple Myeloma, Relapsed/Refractory Multiple Myeloma	Phase 2	Recruiting	C4 Therapeutics, Inc.	100	2026-02-18	2026-08-06
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects Cemsidomide, Elranatamab - Multiple Myeloma (MM)	Phase 1	Recruiting	C4 Therapeutics, Inc.	60	2026-02-06	2026-08-12
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors CFT1946, Trametinib, Cetuximab - Solid Tumors, Melanoma	Phase 1	Completed	C4 Therapeutics, Inc.	89	2022-12-08	2025-11-21
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors CFT8634 - Synovial Sarcoma, Soft Tissue Sarcoma	Phase 1	Terminated	C4 Therapeutics, Inc.	49	2022-03-25	2024-12-17
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma cemsidomide, Dexamethasone Oral - Multiple Myeloma, Lymphoma, Non-Hodgkin's	Phase 1	Active not recruiting	C4 Therapeutics, Inc.	224	2021-04-27	2026-03-25

United States (5) · United Kingdom (2) · France (1) · Germany (1) · Spain (1)